OTCMKTS:SGIOY Shionogi & Co., Ltd. (SGIOY) Stock Price, News & Analysis $6.81 -0.01 (-0.13%) (As of 11/15/2024 05:39 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest About Shionogi & Co., Ltd. Stock (OTCMKTS:SGIOY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Shionogi & Co., Ltd. alerts:Sign Up Key Stats Today's Range$6.66▼$6.8450-Day Range$6.75▼$11.4752-Week Range$6.22▼$9.11Volume508,352 shsAverage Volume183,205 shsMarket Capitalization$12.12 billionP/E Ratio11.61Dividend Yield1.76%Price TargetN/AConsensus RatingN/A Company OverviewShionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.Read More… Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Shionogi & Co., Ltd. Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks20th Percentile Overall ScoreSGIOY MarketRank™: Shionogi & Co., Ltd. scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Shionogi & Co., Ltd.. Earnings and Valuation1.3 / 5Proj. Earnings Growth-3.70% Earnings GrowthEarnings for Shionogi & Co., Ltd. are expected to decrease by -3.70% in the coming year, from $0.27 to $0.26 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Shionogi & Co., Ltd. is 11.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 109.33.Price to Earnings Ratio vs. SectorThe P/E ratio of Shionogi & Co., Ltd. is 11.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 62.60.Price to Earnings Growth RatioShionogi & Co., Ltd. has a PEG Ratio of 4.62. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioShionogi & Co., Ltd. has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the outstanding shares of Shionogi & Co., Ltd. have been sold short.Short Interest Ratio / Days to CoverShionogi & Co., Ltd. has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Shionogi & Co., Ltd. has recently increased by 560.77%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldShionogi & Co., Ltd. pays a meaningful dividend of 1.76%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthShionogi & Co., Ltd. does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Shionogi & Co., Ltd. is 20.45%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Shionogi & Co., Ltd. will have a dividend payout ratio of 46.15% next year. This indicates that Shionogi & Co., Ltd. will be able to sustain or increase its dividend.Read more about Shionogi & Co., Ltd.'s dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the outstanding shares of Shionogi & Co., Ltd. have been sold short.Short Interest Ratio / Days to CoverShionogi & Co., Ltd. has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Shionogi & Co., Ltd. has recently increased by 560.77%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News SentimentShionogi & Co., Ltd. has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Shionogi & Co., Ltd. this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Shionogi & Co., Ltd. insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 1.92% of the stock of Shionogi & Co., Ltd. is held by institutions.Read more about Shionogi & Co., Ltd.'s insider trading history. Receive SGIOY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shionogi & Co., Ltd. and its competitors with MarketBeat's FREE daily newsletter. Email Address SGIOY Stock News HeadlinesShionogi's Xocova effective in preventing symptomatic COVID-19: studyOctober 30, 2024 | msn.comJapan's Shionogi says Phase 3 study showed COVID pill reduces transmissionOctober 29, 2024 | msn.comLet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! November 17, 2024 | DTI (Ad)Jefferies Sticks to Its Hold Rating for Shionogi & Co (SGIOF)October 28, 2024 | markets.businessinsider.comShionogi & Co., Ltd. (4507.T)October 27, 2024 | finance.yahoo.comSGIOF Shionogi & Co., Ltd.September 25, 2024 | seekingalpha.comShionogi & Co., Ltd. (SGIOY) Q1 2024 Earnings Call TranscriptJuly 30, 2024 | seekingalpha.comShionogi earnings preview: what to expectJuly 29, 2024 | markets.businessinsider.comSee More Headlines SGIOY Stock Analysis - Frequently Asked Questions How have SGIOY shares performed this year? Shionogi & Co., Ltd.'s stock was trading at $11.9720 at the beginning of 2024. Since then, SGIOY stock has decreased by 43.1% and is now trading at $6.8110. View the best growth stocks for 2024 here. How were Shionogi & Co., Ltd.'s earnings last quarter? Shionogi & Co., Ltd. (OTCMKTS:SGIOY) issued its quarterly earnings data on Wednesday, January, 31st. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.33 by $0.11. The company had revenue of $719.72 million for the quarter. Shionogi & Co., Ltd. had a trailing twelve-month return on equity of 11.95% and a net margin of 35.53%. How do I buy shares of Shionogi & Co., Ltd.? Shares of SGIOY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings1/31/2024Today11/16/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryPersonal Services Current SymbolOTCMKTS:SGIOY CUSIPN/A CIK1281721 Webwww.shionogi.co.jp Phone(166) 202-2161FaxN/AEmployees5,680Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.5867 Trailing P/E Ratio11.61 Forward P/E Ratio26.20 P/E Growth5.34Net Income$1.12 billion Net Margins35.53% Pretax Margin45.57% Return on Equity11.95% Return on Assets10.56% Debt Debt-to-Equity Ratio0.01 Current Ratio5.86 Quick Ratio5.37 Sales & Book Value Annual Sales$3.01 billion Price / Sales4.02 Cash Flow$0.70 per share Price / Cash Flow9.67 Book Value$4.86 per share Price / Book1.40Miscellaneous Outstanding Shares1,779,260,000Free FloatN/AMarket Cap$12.12 billion OptionableNot Optionable Beta0.22 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (OTCMKTS:SGIOY) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shionogi & Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shionogi & Co., Ltd. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.